Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer -

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cancers | Gastrointestinal disorders
Summary
RCT (n=800) found that in patients with refractory colorectal cancer, TAS-102 (oral agent combining trifluridine and tipiracil hydrochloride), as compared with placebo, was linked to improvement in overall survival (7.3 vs. 5.1 months; HR 0.68; 95% CI, 0.58-0.81; p<0.001).
UKMi comment
In March 2015, TAS-102 was filed for approval in the EU for the treatment of metastatic colorectal cancer in adults previously treated with, or not considered suitable for fluoropyrimidine-based chemotherapy, anti-VEGF therapy, and/or anti-EGFR therapy.
Related links: